The US Food and Drug Administration (FDA) has approved inclisiran (Leqvio) as an adjunct to statins for further reduction of LDL cholesterol levels, the drug's developer, Novartis, announced today.
Dr James Chambers discusses handling a patient enquiry about inclisiran, including how to explain current evidence for its ...
Credit: Novartis. The approval was based on data from the ORION-9, ORION-10, and ORION-11 trials that evaluated Leqvio in patients 18 years of age and older with HeFH or clinical ASCVD. The Food and ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Longer-term follow-up of high-risk patients treated with inclisiran (Leqvio; Novartis) shows that the early reductions in LDL-cholesterol levels are sustained over several years, according to results ...
WASHINGTON, DC — Treatment with inclisiran (Alnylam Pharmaceuticals/the Medicines Company), which suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) synthesis in the liver, can ...
More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results